Evidence map›Paper›PMID 33885923›Full record

ArticleAnnals of hematology2021

The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimen.

Peng Ke, Xinyou Zhang, Songbai Liu, Qian Zhu, Xiao Ma, Feng Chen, Xiaowen Tang, Yue Han, ZhengZheng Fu, Suning Chen and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Peng Ke *Department of Hematology, Shenzhen People's Hospital, Second Clinical Medical College of Jinan University, First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China.
Xinyou Zhang *Department of Hematology, Shenzhen People's Hospital, Second Clinical Medical College of Jinan University, First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China.
Songbai Liu *Suzhou Key laboratory for medical biotechnology, Suzhou Vocational Health College, Suzhou, China.
Qian Zhu *Soochow Hopes Hematonosis Hospital, Suzhou, China.
Xiao MaNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China.
Feng ChenNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China.
Xiaowen TangNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China.
Yue HanNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China.
ZhengZheng FuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China.
Suning ChenNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China.
Depei WuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China.
Huiying QiuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China. qiuhuiying@aliyun.com.
Jihao ZhouDepartment of Hematology, Shenzhen People's Hospital, Second Clinical Medical College of Jinan University, First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China. zhoujihao@aliyun.com.
Xiebing BaoNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China. baosuyixueye@163.com.
Soochow University · CNFirst Affiliated Hospital of Soochow University · CNSouthern University of Science and Technology · CNSuzhou Vocational Health College · CN

Funding

Discipline Construction Capacity Upgrading Project of Shenzhen Municipal Health Commission SZXJ2018020Jiangsu Medical Outstanding Talents Project (JCRCA2016002), Jiangsu Provincial Key Medical Center YXZXA2016002Key R&D Program of Jiangsu Province BE2018652National Key R&D Program of China 2017YFA0104502National Natural Science Foundation of China 81730003National Science and Technology Major Project 2017ZX09304021Priority Academic Program Development of Jiangsu Higher Education Institutions PAPD
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) viremia is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The purpose of this study was to evaluate the impacts of early-onset EBV viremia in acute leukemia (AL) patients who underwent allo-HSCT with anti-thymocyte globulin (ATG)-containing myeloablative conditioning (MAC) regimen. Two hundred and ninety-six patients were included between January 2013 and December 2015. In 126 patients (42.6%) who developed early-onset EBV viremia, with a median time of 48 (range 18~99) days after allo-HSCT. The cumulative incidence of EBV viremia at 30 and 90 days after allo-HSCT were 4.1 and 39.9%, respectively. Prognostic analysis showed that the adjusted overall survival in early-EBV

Indexed as

Hematopoietic Stem Cell TransplantationAdultAllograftsAntilymphocyte SerumCytomegalovirusCytomegalovirus InfectionsEpstein-Barr Virus InfectionsFemaleGraft vs Host DiseaseHerpesvirus 4, HumanHistocompatibilityHumansImmunosuppressive AgentsLeukemia, Myeloid, AcuteMaleMyeloablative AgonistsAntilymphocyte SerumImmunosuppressive AgentsMyeloablative AgonistsAcute leukemiaAllogeneic hematopoietic stem cell transplantationATGEarly viremiaEpstein-Barr virusPrognosis

Identifiers

PMID33885923
OpenAlexW3155504955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.